Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 158 of the 159 references it cites were found in a registry or an index.

HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation

Open access
Zhang, Qian-qian, Zhang, Wei-jie, Chang, Sheng · 2023 · Frontiers in Immunology

Abstract

Histone deacetylase 6 (HDAC6), an almost exclusively cytoplasmic enzyme, plays an essential role in many biological processes and exerts its deacetylation-dependent/independent effects on a variety of target molecules, which has contributed to the flourishing growth of relatively isoform-specific enzyme inhibitors. Renal transplantation (RT) is one of the alternatively preferred treatments and the most cost-effective treatment approaches for the great majority of patients with end-stage renal disease (ESRD). HDAC6 expression and activity have recently been shown to be increased in kidney disease in a number of studies. To date, a substantial amount of validated studies has identified HDAC6 as a pivotal modulator of innate and adaptive immunity, and HDAC6 inhibitors (HDAC6i) are being developed and investigated for use in arrays of immune-related diseases, making HDAC6i a promising therapeutic candidate for the management of a variety of renal diseases. Based on accumulating evidence, HDAC6i markedly open up new avenues for therapeutic intervention to protect against oxidative stress–induced damage, tip the balance in favor of the generation of tolerance-related immune cells, and attenuate fibrosis by inhibiting multiple activations of cell profibrotic signaling pathways. Taken together, we have a point of view that targeting HDAC6 may be a novel approach for the therapeutic strategy of RT-related complications, including consequences of ischemia-reperfusion injury, induction of immune tolerance in transplantation, equilibrium of rejection, and improvement of chronic renal graft interstitial fibrosis after transplantation in patients. Herein, we will elaborate on the unique function of HDAC6, which focuses on therapeutical mechanism of action related to immunological events with a general account of the tantalizing potential to the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1168848

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic depiction of the different isoforms of HDAC. N, N-terminus; C, C-terminus; Blue lines depict the length of the protein; Yellow bars depict catalytic domains; Orange bars depict nuclear localization sequences (NLS); Brown bars depict nuclear export sequences (NES1, NES2); Green bar depicts Ser-Glu containing a tetradecapeptide repeating domain (SE14); Purple bar depicts a zinc-finger ubiquitin-binding domain (ZnF-UBD).
Figure 1 Schematic depiction of the different isoforms of HDAC. N, N-terminus; C, C-terminus; Blue lines depict the length of the protein; Yellow bars depict catalytic domains; Orange bars depict nuclear localization sequences (NLS); Brown bars depict nuclear export sequences (NES1, NES2); Green bar depicts Ser-Glu containing a tetradecapeptide repeating domain (SE14); Purple bar depicts a zinc-finger ubiquitin-binding domain (ZnF-UBD).CC BY · PubMed Central
Figure 2 Description of HDAC6 on IRI pathways. IRI causes immune cells of both the innate and adaptive immune systems, such as neutrophils, DCs, macrophages, and lymphocyte subsets contribute to the pathogenesis and pathological processes of IRI. IRI-generated ROS promotes activation of the NF-κB and AP-1 signaling pathways with subsequent transcription and production of inflammatory cytokines signaling mechanisms and transcriptional regulatory pathways. HDAC6 deacetylate histone and non-histone proteins, which blockage-elicited renal protection is associated with inhibition of suppression of inflammatory responses, and reduction of oxidative stress. HDAC6 inhibitions dampen the expression of ROS with subsequent transcription and production of proinflammatory cytokines by inhibiting the NF-κB and AP-1 signaling pathways.
Figure 2 Description of HDAC6 on IRI pathways. IRI causes immune cells of both the innate and adaptive immune systems, such as neutrophils, DCs, macrophages, and lymphocyte subsets contribute to the pathogenesis and pathological processes of IRI. IRI-generated ROS promotes activation of the NF-κB and AP-1 signaling pathways with subsequent transcription and production of inflammatory cytokines signaling mechanisms and transcriptional regulatory pathways. HDAC6 deacetylate histone and non-histone proteins, which blockage-elicited renal protection is associated with inhibition of suppression of inflammatory responses, and reduction of oxidative stress. HDAC6 inhibitions dampen the expression of ROS with subsequent transcription and production of proinflammatory cytokines by inhibiting the NF-κB and AP-1 signaling pathways.CC BY · PubMed Central
Figure 3 Mechanisms of graft tolerance (A) and rejection (B) consist of complex processes involving the induction of proinflammatory APCs and tolerogenic DCs, leading to a different microenvironment. (1) HDAC6 promotes the expression of T-bet in the Th1 master regulating the ratio of Th1 to Th2, which also controls the population of CD4 cells, and the CD4T-bet/CD4T-GATA-3 ratio was significantly reduced in the HDAC6i group. in the HDAC6i group. (2) Acetylation promotes Foxp3 dimerisation, DNA binding and transcriptional activity, and expansion of the Treg population, and is ultimately associated with immune tolerance. The effects are likely to be related to increased Foxp3 acetylation and consequent expansion of Tregs. (3) HDAC6 inhibitor upregulates the Treg cell population through the STAT3/IL-10 tolerogenic axis to overcome immune tolerance and tilt the balance towards T-cell immunity. HDAC6 improved the expression levels of TF Rora in Th17, IL-17A secretion in Th17 cells and IL-4 levels secreted by Tregs, Th2 induced, as well as the differentiation of TH17/Treg imbalance. HDAC6i has therapeutic effects on the pathology of acute rejection by targeting the HDAC6/HIF-1a/ROR gt/Th17 signalling axis.
Figure 3 Mechanisms of graft tolerance (A) and rejection (B) consist of complex processes involving the induction of proinflammatory APCs and tolerogenic DCs, leading to a different microenvironment. (1) HDAC6 promotes the expression of T-bet in the Th1 master regulating the ratio of Th1 to Th2, which also controls the population of CD4 cells, and the CD4T-bet/CD4T-GATA-3 ratio was significantly reduced in the HDAC6i group. in the HDAC6i group. (2) Acetylation promotes Foxp3 dimerisation, DNA binding and transcriptional activity, and expansion of the Treg population, and is ultimately associated with immune tolerance. The effects are likely to be related to increased Foxp3 acetylation and consequent expansion of Tregs. (3) HDAC6 inhibitor upregulates the Treg cell population through the STAT3/IL-10 tolerogenic axis to overcome immune tolerance and tilt the balance towards T-cell immunity. HDAC6 improved the expression levels of TF Rora in Th17, IL-17A secretion in Th17 cells and IL-4 levels secreted by Tregs, Th2 induced, as well as the differentiation of TH17/Treg imbalance. HDAC6i has therapeutic effects on the pathology of acute rejection by targeting the HDAC6/HIF-1a/ROR gt/Th17 signalling axis.CC BY · PubMed Central
Figure 4 Schematic illustration of the anti-fibrotic property of HDAC6i in renal transplantation. Injured tissue or activated immune cells secrete profibrotic factors that induce fibroblast differentiation into myofibroblasts. Myofibroblasts actively synthesise extracellular matrix. HDAC6i negatively regulates fibrosis. (1) In the initial stage of the pro-fibrotic process, intra-graft inflammation, an integral part of the host defence mechanism in response to injury, is activated. Through modulation of p38 MAPK, NF-kB and AP-1 pathways, several pro-inflammatory, pro-fibrotic cytokines and adhesion molecules (MMP-1, MMP-2, MMP-9, MCP-1) are secreted by tubular cells with consequent recruitment of inflammatory infiltrates (lymphocytes, macrophages, DCs, neutrophils) that may facilitate the recruitment of new interstitial mononuclear cells. (2) Macrophages are a major source of TGF-b, which modulates the production of IL-1β, TNF-α, IFN-bγ and IL-10 and induces myofibroblast differentiation and the production of ECM proteins. (3) Damaged mitochondria mediate apoptosis and necrosis with the consequent release of DAMPs, which activate the NLRP3 inflammasome and participate in the prosis of fibrosis. (4) ROS accumulation via IRI, NADPH oxidase and mitochondrial dysfunction contribute to EMT. (5) Inhibition of HDAC6 attenuated EGFR, TGF-b1 induced EMT markers, which is accompanied by HDAC6-dependent deacetylation of a -tubulin. (6) The underlying mechanism by which HDAC6 inhibition can attenuate fibrosis by inhibiting profibrotic genes, multiple activations of cell pro-fibrotic signalling pathways and inflammation. Dashed arrows indicate indirect pro-fibrotic effects.
Figure 4 Schematic illustration of the anti-fibrotic property of HDAC6i in renal transplantation. Injured tissue or activated immune cells secrete profibrotic factors that induce fibroblast differentiation into myofibroblasts. Myofibroblasts actively synthesise extracellular matrix. HDAC6i negatively regulates fibrosis. (1) In the initial stage of the pro-fibrotic process, intra-graft inflammation, an integral part of the host defence mechanism in response to injury, is activated. Through modulation of p38 MAPK, NF-kB and AP-1 pathways, several pro-inflammatory, pro-fibrotic cytokines and adhesion molecules (MMP-1, MMP-2, MMP-9, MCP-1) are secreted by tubular cells with consequent recruitment of inflammatory infiltrates (lymphocytes, macrophages, DCs, neutrophils) that may facilitate the recruitment of new interstitial mononuclear cells. (2) Macrophages are a major source of TGF-b, which modulates the production of IL-1β, TNF-α, IFN-bγ and IL-10 and induces myofibroblast differentiation and the production of ECM proteins. (3) Damaged mitochondria mediate apoptosis and necrosis with the consequent release of DAMPs, which activate the NLRP3 inflammasome and participate in the prosis of fibrosis. (4) ROS accumulation via IRI, NADPH oxidase and mitochondrial dysfunction contribute to EMT. (5) Inhibition of HDAC6 attenuated EGFR, TGF-b1 induced EMT markers, which is accompanied by HDAC6-dependent deacetylation of a -tubulin. (6) The underlying mechanism by which HDAC6 inhibition can attenuate fibrosis by inhibiting profibrotic genes, multiple activations of cell pro-fibrotic signalling pathways and inflammation. Dashed arrows indicate indirect pro-fibrotic effects.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 159 references

Research works printed but not linked: 11

  1. Zhao, 2016, Inhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model, J Trauma Acute Care Surg, 80, 34, 10.1097/ta.0000000000000897 · DOI
  2. Savoye, 2021, Optimal donation of kidney transplants after controlled circulatory death, Am J Transplant, 21, 10.1111/ajt.16425 · DOI
  3. Yan, 2018, Histone deacetylase 6 modulates macrophage infiltration during inflammation, Theranostics, 8, 10.7150/thno.25317 · DOI
  4. Ledezma, 2020, Indocyanine green-nexturastat a-PLGA nanoparticles combine photothermal and epigenetic therapy for melanoma, Nanomater (Basel), 10, 10.3390/nano10010161 · DOI
  5. Tsuji, 2015, Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation, J Allergy Clin Immunol, 135, 10.1016/j.jaci.2014.10.002 · DOI
  6. Beier, 2012, Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms, Sci Signal, 5, ra45, 10.1126/scisignal.2002873 · DOI · Paper page
  7. Qiu, 2020, Targeting histone deacetylase 6 reprograms interleukin-17-Producing helper T cell pathogenicity and facilitates immunotherapies for hepatocellular carcinoma, Hepatology, 71, 10.1002/hep.30960 · DOI
  8. Ellis, 2017, Mechanisms by which b cells and regulatory T cells influence development of murine organ-specific autoimmune diseases, J Clin Med, 6, 10.3390/jcm6020013 · DOI
  9. Ganguly, 2015, Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia, Oncotarget, 6, 10.18632/oncotarget.5167 · DOI
  10. Cheng, 2015, Selective histone deacetylase 6 inhibition prolongs survival in a lethal two-hit model, J Surg Res, 197, 39, 10.1016/j.jss.2015.02.070 · DOI
  11. Osko, 2019, Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes, Methods Enzymol, 626, 10.1016/bs.mie.2019.06.028 · DOI

Cited by

See all 24

Metadata

Authors
Zhang, Q.-Q., Zhang, W.-J., & Chang, S.
Affiliations
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Corresponding author
Chang, Sheng
Venue
Frontiers in Immunology
Published
2023-07-21
Volume
14
Pages
1168848-1168848
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4385116382
Cited by
24
References
159
Citations by year
2026: 6 · 2025: 7 · 2024: 9 · 2023: 2
FWCI
0.63
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
HDAC6, HDAC6 inhibitors, kidney transplantation, end-stage renal disease, immune tolerance, graft rejection, ischemia-reperfusion injury, interstitial fibrosis, oxidative stress, histone deacetylase, immunomodulation
MeSH terms
Histone Deacetylase 6, Fibrosis, Humans, Kidney Diseases, Signal Transduction, Kidney Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation. https://app.cochat.ai/papers/10.3389/fimmu.2023.1168848
The paper
Zhang, Q.-Q., Zhang, W.-J., & Chang, S. (2023). HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1168848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.